Publication: Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Information

PGS Catalog Publication (PGP) ID: PGP000047
PubMed ID: 29321194
doi: 10.1136/bmj.j5757

Publication Date: Jan. 10, 2018

Journal: BMJ

Authors: Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Garcia SB, Muir K, Grönberg H, Wiklund F, Aly M, Schleutker J, Sipeky C, Tammela TL, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Cuk K, Saum KU, Park JY, Sellers TA, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Karow DS, Mills IG, Andreassen OA, Dale AM, PRACTICAL Consortium*.

PGS Associated with PGP000047

PGS Developed By This Study

PGS Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.
PGS Performance Metric (PPM) ID Evaluated Score PGS Catalog Sample Set (PSS) ID Performance Source Trait PGS Effect Sizes
(per SD change)
PGS Classification Metrics Other Metrics Covariates Included in PGS Model PGS Performance: Other Relevant Information
PPM000182 PGS000067 (PCa_PHS) PSS000105 Seibert TM et al. (2018) Reported Trait: aggressive prostate cancer HR (Hazard ratio; top 2% vs. average risk): 2.9 [2.4 - 3.4]
PPM000183 PGS000067 (PCa_PHS) PSS000105 Seibert TM et al. (2018) Reported Trait: aggressive prostate cancer (age at onset) z-test (p-value) < 1e-16
PPM000184 PGS000067 (PCa_PHS) PSS000106 Seibert TM et al. (2018) Reported Trait: any prostate cancer HR (Hazard ratio; top 2% vs. average risk): 2.5 [2.2 - 2.8]
PPM000185 PGS000067 (PCa_PHS) PSS000106 Seibert TM et al. (2018) Reported Trait: any prostate cancer (age at onset) z-test (p-value) < 1e-16
PPM000186 PGS000067 (PCa_PHS) PSS000107 Seibert TM et al. (2018) Reported Trait: very aggressive prostate cancer HR (Hazard ratio; top 2% vs. average risk): 3.0 [2.2 - 4.0]
PPM000187 PGS000067 (PCa_PHS) PSS000107 Seibert TM et al. (2018) Reported Trait: very aggressive prostate cancer (age at onset) z-test (p-value) < 1e-11

Evaluated Samples

PGS Catalog Sample Set (PSS) ID Detailed Phenotype Description (e.g. ICD/SNOMED codes used to identify cases) Sample Numbers Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000105 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals
100.00 % Male samples
European ProtecT
PSS000105 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of aggressive prostate cancer (defined as any of Gleason score ≥7, stage T3-T4, PSA concentration ≥10 ng/mL, nodal metastasis, or distant metastasis) 628 individuals
[ 628 cases]
100.00 % Male samples
European ProtecT
PSS000106 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals
100.00 % Male samples
European ProtecT
PSS000106 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of prostate cancer. 1,583 individuals
[ 1,583 cases]
100.00 % Male samples
European ProtecT
PSS000107 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals
100.00 % Male samples
European ProtecT
PSS000107 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of very aggressive prostate cancer (defined as any of Gleason score ≥8, stage T3-4, positive nodes, or distant metastases) 220 individuals
[ 220 cases]
100.00 % Male samples
European ProtecT